Medifocus, Inc. Announces Engagement of Maxim Group LLC

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT
INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN
THE UNITED STATES. 


Medifocus Inc. (the "Company") (OTCQX:MDFZF)(TSX VENTURE:MFS) is pleased to
announce that it has entered into an Engagement Agreement (the "Agreement") with
New York City based Maxim Group LLC ("Maxim") whereby Maxim will act as the
Company's exclusive placement agent for a private placement of the Company's
securities (the "Proposed Offering"). The Agreement is in effect until October
31, 2014, after which time either party may terminate the Agreement upon thirty
30 days prior written notice to the other party.


"We are excited by the engagement of Maxim and the opportunities that may emerge
as a result of such engagement," said Dr. Augustine Y. Cheung, President and
Chief Executive Officer of the Company. "We believe that this engagement and the
potential financing in connection with this engagement will enable the Company
to continue the commercialization of our current products, as well as allow us
to develop additional cancer treatment products that utilize our proprietary
technology."


Pursuant to the Agreement, the offering will be made on a best efforts basis and
the terms of the offering will be determined by the Company and Maxim. The
Company has agreed to provide the following compensation to Maxim: (i) a
financing placement fee equal to 9.0% of the gross proceeds of the Proposed
Offering; (ii) the grant of warrants covering a number of the Company's
securities equal to 9.0% of the total number of securities sold and/or issued in
the Proposed Offering; and (iii) reimbursement of certain expenses. The terms of
Maxim's compensation and the Proposed Offering are subject both to compliance
with TSX Venture Exchange policies, and the final approval of the TSX Venture
Exchange. 


The Company intends to use the net proceeds expected to be received from the
Proposed Offering to: (1) accelerate the commercialization of the
Company'sProlieve(R) technology in the United States; (2) expandmanufacturing of
Prolieve(R) systems and marketing efforts in connection with the Company's
expansion in international markets; (3) bring the Company's Phase III clinical
studies for its APA 1000 Breast Cancer System to a midpoint analysis, with 119
patients enrolled; (4) develop of additional cancer treatment productsthat
utilize the Company's Endo-thermotherapy Platform and Adaptive Phased Array
Microwave Focusing Platform; and (5) foradditional working capital and general
corporate purposes.


The securities referred to in this news release have not been, nor will they be,
registered under the United States Securities Act of 1933, as amended, and may
not be offered or sold within the United States or to, or for the account or
benefit of, U.S. persons absent U.S. registration or an applicable exemption
from theU.S. registration requirements. This news release does not constitute an
offer for sale of securities or a solicitation for offers to buy any securities.
Any public offering of securities in the United States must be made by means of
a prospectus containing detailed information about the company and management,
as well as financial statements. 


About Maxim Group (www.maximgrp.com) 

Maxim Group is a U.S. based leading investment banking, securities and
investment management firm that provides an array of financial services
including: investment banking, equity research, private wealth management,
structured products, and global institutional equity, fixed-income and
derivative sales & trading to a diverse range of corporate clients,
institutional investors and high net worth individuals. Maxim Group is
registered as a broker-dealer with the U.S. Securities and Exchange Commission
and is a member of the following: Financial Industry Regulatory Authority
("FINRA"); Municipal Securities Rulemaking Board ("MSRB"); Securities Insurance
Protection Corporation ("SIPC"); NASDAQ Stock Market; and NYSE Arca, Inc.


About Medifocus, Inc.

Medifocus, Inc. owns two fully developed technology platforms with comprehensive
United States and international patent protection. First, the Company owns the
Endo-thermotherapy Platform-a catheter-basis focused heat technology platform
that utilizes natural body openings to deliver precise microwave thermotherapy
to the diseased sites. The Company's Prolieve(R) Thermodilatation System, a
United States Food and Drugs Administration ("FDA")-approved device for the
treatment of Benign Prostatic Hyperplasia ("BPH"), was developed based on the
Endo-thermotherapy Platform and is currently generating revenue. Additionally,
theAdaptive Phased Array ("APA") Microwave Focusing Platform, invented by the
Massachusetts Institute of Technology and licensed to the Company, directs
precisely focused microwave energy at tumor centers to induce shrinkage or
eradication of tumors without undue harm to surrounding tissue.The Company's APA
1000 Breast Cancer Treatment System, developed from the APA technology platform,
has received approval from the FDA and Health Canada to conduct pivotal Phase
III clinical trials. The Company believes that these two technology platforms
can provide the design basis for the development of multiple cancer treatment
systems for surface, subsurface and deep seated localized and regional cancers.
Please visit www.medifocusinc.com, www.prolieve.com and
http://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627 for
more details. 


Forward-Looking Statements and Information

This news release contains "forward-looking statements" and "forward-looking
information", which may not be based on historical facts. Forward-looking
statements and forward-looking information, include, but are not limited to,
information and statements with respect the structure and the proceeds of the
Proposed Offering and the expected use of the proceeds. Forward-looking
statements are frequently characterized by words such as "plan," "expect,"
"project," "intend," "believe," "anticipate", "estimate" and other similar
words, or statements that certain events or conditions "may" or "will" occur.
Forward-looking statements are based on the opinions and estimates of management
at the date the statements are made. Such forward-looking statements and
forward-looking information involve known and unknown risks, uncertainties and
other factors that may cause the actual results events or developments to be
materially different from any future results, events or developments expressed
or implied by such forward-looking statements or forward-looking information.
These factors should be considered carefully and readers are cautioned not to
place undue reliance on such forward-looking statements and forward-looking
information. Except as required by applicable securities laws, the Company
disclaims any obligation to update any such factors or to publicly announce the
results of any revisions to any of the forward-looking statements or
forward-looking information contained herein to reflect future results, events
or developments.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Medifocus Contact:
John Mon COO
Medifocus, Inc.
410-290-5734
[e-mail]


Investor Relations Contact:
Robert Giordano
Consulting for Strategic Growth 1
917-327-3938
[e-mail]